Littérature scientifique sur le sujet « SSc: progressive systemic sclerosi »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « SSc: progressive systemic sclerosi ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "SSc: progressive systemic sclerosi"
Ananyeva, L. P., I. E. Tyurin, O. A. Koneva, L. A. Garzanova et A. M. Lila. « Interstitial lung disease in systemic sclerosis (systemic scleroderma) ». Modern Rheumatology Journal 15, no 1S (17 mars 2021) : 1–62. http://dx.doi.org/10.14412/1996-7012-2021-1s-1-62.
Texte intégralTang, Iris Yan Ki, et So Ho. « Treatment of Systemic Sclerosis Associated Interstitial Lung Disease ». Journal of Clinical Rheumatology and Immunology 20, no 02 (19 novembre 2020) : 56–64. http://dx.doi.org/10.1142/s2661341720300050.
Texte intégralRuaro, Barbara, Marco Confalonieri, Marco Matucci-Cerinic, Francesco Salton, Paola Confalonieri, Mario Santagiuliana, Gloria Maria Citton, Elisa Baratella et Cosimo Bruni. « The Treatment of Lung Involvement in Systemic Sclerosis ». Pharmaceuticals 14, no 2 (13 février 2021) : 154. http://dx.doi.org/10.3390/ph14020154.
Texte intégralMANETTI, MIRKO, ANNA FRANCA MILIA, SERENA GUIDUCCI, ELOISA ROMANO, MARCO MATUCCI-CERINIC et LIDIA IBBA-MANNESCHI. « Progressive Loss of Lymphatic Vessels in Skin of Patients with Systemic Sclerosis ». Journal of Rheumatology 38, no 2 (15 novembre 2010) : 297–301. http://dx.doi.org/10.3899/jrheum.100767.
Texte intégralHerrick, Ariane L. « Advances in the Treatment of Systemic Sclerosis ». Rheumatology 1, no 2 (2022) : 61. http://dx.doi.org/10.17925/rmd.2022.1.2.61.
Texte intégralGiovannetti, Antonello, Elisabetta Straface, Edoardo Rosato, Marco Casciaro, Giovanni Pioggia et Sebastiano Gangemi. « Role of Alarmins in the Pathogenesis of Systemic Sclerosis ». International Journal of Molecular Sciences 21, no 14 (15 juillet 2020) : 4985. http://dx.doi.org/10.3390/ijms21144985.
Texte intégralSaketkoo, Lesley Ann, Mary Beth Scholand, Matthew R. Lammi et Anne-Marie Russell. « Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials ». Journal of Scleroderma and Related Disorders 5, no 2_suppl (mars 2020) : 48–60. http://dx.doi.org/10.1177/2397198320904178.
Texte intégralMackintosh, John A., Anna Stainer, Joseph L. Barnett et Elisabetta A. Renzoni. « Systemic Sclerosis Associated Interstitial Lung Disease : A Comprehensive Overview ». Seminars in Respiratory and Critical Care Medicine 40, no 02 (avril 2019) : 208–26. http://dx.doi.org/10.1055/s-0039-1683431.
Texte intégralZhang, Xuli Jerry, Ashley Bonner, Marie Hudson, Murray Baron et Janet Pope. « Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in Systemic Sclerosis ». Journal of Rheumatology 40, no 6 (1 avril 2013) : 850–58. http://dx.doi.org/10.3899/jrheum.120705.
Texte intégralNagy, Tamas, Nora Melinda Toth, Erik Palmer, Lorinc Polivka, Balazs Csoma, Alexandra Nagy, Noémi Eszes et al. « Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry ». Biomedicines 10, no 9 (31 août 2022) : 2129. http://dx.doi.org/10.3390/biomedicines10092129.
Texte intégralThèses sur le sujet "SSc: progressive systemic sclerosi"
PATUZZO, Giuseppe. « Pathogenesis of Systemic Sclerosis : pro-inflammatory role of ET-1 receptors ». Doctoral thesis, 2014. http://hdl.handle.net/11562/695560.
Texte intégralEndothelin-1 (ET-1) plays a pivotal role in vasoconstriction, fibrosis and inflammation, the three major aspects in the pathogenesis of Systemic Sclerosis (SSc). ET-1 receptors are ETA and ETB. The receptors are expressed on the majority of cells involved in SSc, such as endothelial cells, smooth muscle cells and fibroblasts. Little is known about the expression of ET-1 receptors on leukocytes, except for macrophages and monocytes; there is no information about the expression of ETA and ETB on lymphocytes, neutrophils and other cells involved in the innate and acquired immune response. Endothelin receptors antagonists are used in the treatment of scleroderma patients with recurrent ischemic digital ulcers and/or pulmonary arterial hypertension. They have beneficial effects on vasoconstriction and fibrosis, but less is known about their anti-inflammatory role. We aimed at studying the link between ET-1 and inflammation in SSc. Since T and B cells, monocytes and neutrophils are among the most important cells in inflammatory responses in SSc, we studied ETA and ETB expression on these cells with flow cytometry, and also ETA- and ETB-coding mRNA expression in T CD4+ cells and neutrophils by RT-PCR. We have studied the different expression of receptors on T and B cell and monocytes between patients and controls, the correlations of the expression with the cutaneous form of disease, with Bosentan therapy, and ischemic digital ulcers, pulmonary arterial hypertension and interstitial lung disease. We also studied the receptors modulation on activated T cells by flow cytometry. In order to evaluate the pro-inflammatory effects of ET-1 and the anti-inflammatory role of Bosentan, we studied how ET-1 influences IFN-γ and IL-4 production by T CD4+ cells, with or without receptors blockage. We also studied the expression of IFN-γ-, IL-4- IL-6-, IL-10- and IL-17-coding mRNA in T CD4+ cells by Real Time PCR at different times in order to understand the timing of T CD4+ cells response to stimulation with ET-1. We previously described that T cells and monocytes express both ETA and ETB receptors. We have validated our data in a larger cohort of patients and controls. We confirmed that not only T cells and monocytes but also B lymphocytes and neutrophils express ETA and ETB on their surface. Moreover, the expression of ETA was greater than ETB both in patients and controls in T cells and monocytes, while for B cells there was not difference between ETA and ETB expression. Interesting, neutrophils express both ETA and ETB. Neutrophils participate in the early stages of SSc and contribute to endothelial damages, by production of reactive oxygen species, fibroblasts activation and recruitment T and B cells. ET-1, through ETA and ETB, can contribute to trigger neutrophils activation, that lead to vascular damage. Considering that ETB expression was lower in dSSc- rather than lSSc-patients, ETA signal seemed to be important in the cutaneous profibrotic effects of ET-1. Since a lower ETB expression on monocytes correlated with PAH and a lower ETA expression on T cells correlates with ILD, we can hypothesize that a different pattern of receptors expression is associated with a different response of T cells or monocytes in the preferential induction of PAH or ILD. Therefore ETA or ETB signalling may lead to different clinical features. Considering that ETB expression is increased on activated T cells, ETB signal probably played a major role in inflammation. We also show that activation of ETA and ETB receptors plays an immunomodulatory role, since the production of cytokines changes over time in relation to the stimulation by ET-1 in the presence or absence of the selective blockade of one or both receptors. Furthermore these results support the hypothesis that ET-1 system has a role not only on vasoconstriction and fibrosis but also on inflammation.
Chapitres de livres sur le sujet "SSc: progressive systemic sclerosi"
Tzioufas, Athanasios G., Georgia Liantinioti et Panayotis G. Vlachoyiannopoulos. « Sjogren’s Syndrome (Ss) in Progressive Systemic Sclerosis (SSc) ». Dans In Clinical Practice, 281–97. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-53736-4_23.
Texte intégralTyndall, Alan G. « A 34-Year-Old Woman with 2-Year History of Therapy-Resistant, Rapidly Progressive SSc Successfully Treated by Autologous Hematopoietic Stem Cell Transplantation ». Dans Case Studies in Systemic Sclerosis, 331–37. London : Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-641-2_34.
Texte intégralStrand, Vibeke, Jeremy Sokolove et Alvina D. Chu. « Design of clinical trials in rheumatology ». Dans Oxford Textbook of Rheumatology, 227–36. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_003.
Texte intégralTambo, Torben, et Lars Bækgaard. « Transitioning to Government Shared Services Centres ». Dans Public Affairs and Administration, 419–48. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8358-7.ch019.
Texte intégralTambo, Torben, et Lars Bækgaard. « Transitioning to Government Shared Services Centres ». Dans Advances in Business Information Systems and Analytics, 361–91. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-4518-9.ch011.
Texte intégralActes de conférences sur le sujet "SSc: progressive systemic sclerosi"
Viana Mancuzo, E., L. Arreguy Nogueira, R. Amorim Correa et L. F. Ferreira Pereira. « Assessment of initial dyspnea predicts progression of systemic sclerosis-associated interstitial lung disease (ILD-SSc) at 5 years. » Dans ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2664.
Texte intégralClukers, Johan, Kate Homer, Maarten Lanclus, Dennis Belmans, Cedric Van Holsbeke, Wifried De Backer, Jan De Backer et Dinesh Khanna. « Assessment of disease progression in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients using Functional Respiratory Imaging (FRI) ». Dans ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4805.
Texte intégralKreuter, M., C. P. Denton, L. A. Ho, R. K. Hoyles, I. Glaspole, T. Suda, C. Miede, M. Alves et T. M. Maher. « Progression of systemic sclerosis-associated ILD (SSc-ILD) and effect of nintedanib in subgroups by monocyte and neutrophil counts ». Dans ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.608.
Texte intégralMaher, T. M., O. Distler, Y. Allanore, T. Ogura, J. Varga, S. Vettori, B. Crestani et al. « Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Beyond 52 Weeks : Data from the SENSCIS Trial ». Dans American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4558.
Texte intégral